New Report Says Combination Pharmaceutical Products Are Fast-Gaining Acceptance

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which finds that combination pharmaceutical products, or fixed-dose combinations (FDCs), are highly beneficial and have gained acceptance as well. End Quote

(1888PressRelease) February 27, 2008 - Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which finds that combination pharmaceutical products, or fixed-dose combinations (FDCs), are highly beneficial and have gained acceptance as well.

“Launching Combination Products - Brand Extension and Franchise Development Strategies” reports that FDCs offer benefits to many drug classes as the therapeutic effects get added up and the side-effects get reduced with their use.

The report says that the core advantage of FDCs is an improvement in convenience that stems from reducing prescription numbers and their associated administrative costs.

Authors state that although fixed-dose combination drugs have historically attracted disapproval from physicians, who often prefer to determine the components and ratios of drug applications at their own discretion, a widespread acknowledgement and acceptance of these therapies has now been established.

“Launching Combination Products -Brand Extension and Franchise Development Strategies” finds that combination pharmaceutical products are particularly effective in areas such as HIV and asthma. It finds, however, that the successful positioning of combination products remains difficult in therapeutic areas where combination therapies only provide marginally incremental benefits.

The report contains detailed case studies which also provide unique insights into the brand extension and franchise development strategies of leading companies. Factors contributing to the success behind recent combination product launches are also highlighted.

“Launching Combination Products -Brand Extension and Franchise Development Strategies” is available in pdf format from Piribo. For more information, go to:
http://www.piribo.com/publications/biotechnology/launching_combination_products.html

Piribo product ID: RBI165

About Piribo:
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 7,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

###

Visit Piribo Website

space